AlphaCognition, Inc., a biopharmaceutical company, discovers and develops bioactive compounds for treatments of Alzheimer's and Lou Gehrig's disease. It develops Alpha-1062, for the treatment of mild to moderate Alzheimer's disease, and Alpha-602, for the treatment of amyotrophic lateral sclerosis (ALS). The company was formerly known as Neurodyn Cognition Inc. and changed its name to AlphaCognition, Inc. in March 2020. The company was incorporated in 2014 and is based in Vancouver, Canada with additional offices in Charlottetown, Canada; and West Palm Beach, Florida.
Research context
Crystal Bridge Enterprises Inc appears in PyInvesting’s TSX Venture Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CAD
- Sector
- Financial Services
- Industry
- Shell Companies
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
AlphaCognition, Inc is currently in a long term uptrend where the price is trading 265.8% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Financial Services sector with a price to sales ratio of 0.0.
AlphaCognition, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 173.5% to $-52K since the same quarter in the previous year.
Finally, its free cash flow grew by 61.0% to $-5K since the same quarter in the previous year.
Based on the above factors, AlphaCognition, Inc gets an overall score of 3/5.